MYH9-CACNG2 Fusion FISH Probe
The MYH9-CACNG2 Fusion FISH Probe is used to confirm a fusion of the MYH9 and CACNG2 genes. The fusion of the MYH9 and CACNG2 genes has been associated with Ovarian Serous Cystadenocarcinoma, Lung Adenocarcinoma, Breast Invasive Carcinoma, and Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| MYH9-CACNG2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| MYH9-CACNG2-20-AQAQ | 20 (40 μL) | 200 μL |
|
MYH9 Gene Summary
This gene encodes a conventional non-muscle myosin; this protein should not be confused with the unconventional myosin-9a or 9b (MYO9A or MYO9B). The encoded protein is a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain which is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in this gene have been associated with non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness. [provided by RefSeq, Dec 2011]
Gene Name: Myosin Heavy Chain 9
Chromosome: CHR22: 36677322 -36784063
Locus: 22q12.3
CACNG2 Gene Summary
The protein encoded by this gene is a type I transmembrane AMPA receptor regulatory protein (TARP). TARPs regulate both trafficking and channel gating of the AMPA receptors. The AMPA subtype of ionotropic glutamate receptors are ligand gated ion channels that are typically activated by glutamate released from presynaptic neuron terminals and mediate fast neurotransmission in excitatory synapses. TARPs thus play an important role in synaptic plasticity, learning and memory. Mutations in this gene cause an autosomal dominant form of cognitive disability. [provided by RefSeq, Jul 2017]
Gene Name: Calcium Voltage-gated Channel Auxiliary Subunit Gamma 2
Chromosome: CHR22: 36956915 -37098690
Locus: 22q12.3
Gene Diseases
The MYH9 CACNG2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Ovarian Serous Cystadenocarcinoma |
| Lung Adenocarcinoma |
| Breast Invasive Carcinoma |
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|